person · Reporting owner

Fromkin Andrew J.

Disclosed activity across 2 companies

Tapewire entity: 43180
SEC CIK: 0001341896

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Immunovant, Inc.IMVT · Entity 3632	Director	May 28, 2026	May 29, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Immunovant, Inc.

Report date May 28, 2026 · Filed May 29, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	74,382	Ending reported balance After 2026-05-28 transaction · row 6 6 source rows · reconciled sequence Row 1 · 2026-05-28 · Exercise / conversion · Acquired 31,668 · Balance 131,400 Row 2 · 2026-05-28 · Exercise / conversion · Acquired 71,492 · Balance 202,892 Row 3 · 2026-05-28 · Exercise / conversion · Acquired 77,181 · Balance 280,073 Row 4 · 2026-05-28 · Exercise / conversion · Acquired 16,260 · Balance 296,333 Row 5 · 2026-05-28 · Sale · Disposed 11,483 · Balance 284,850 F1: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.04 - $33.035 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Row 6 · 2026-05-28 · Sale · Disposed 210,468 · Balance 74,382 F2: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.04 - $33.85 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.99 · Expires 2032-08-17	Direct	0	Reported balance After 2026-05-28 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2026-05-28 · Exercise / conversion · Disposed 31,668 · Balance 0 F3: Reflects an award of stock options to purchase Common Shares that is fully vested.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.94 · Expires 2032-01-10	Direct	0	Reported balance After 2026-05-28 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2026-05-28 · Exercise / conversion · Disposed 71,492 · Balance 0 F3: Reflects an award of stock options to purchase Common Shares that is fully vested.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.43 · Expires 2029-11-19	Direct	0	Reported balance After 2026-05-28 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2026-05-28 · Exercise / conversion · Disposed 77,181 · Balance 0 F3: Reflects an award of stock options to purchase Common Shares that is fully vested.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.70 · Expires 2033-04-12	Direct	0	Reported balance After 2026-05-28 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2026-05-28 · Exercise / conversion · Disposed 16,260 · Balance 0 F3: Reflects an award of stock options to purchase Common Shares that is fully vested.

Filing footnotes · ownership attribution and instrument terms

F1: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.04 - $33.035 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

F2: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.04 - $33.85 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

F3: Reflects an award of stock options to purchase Common Shares that is fully vested.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Tobira Therapeutics, Inc.

Report date November 01, 2016 · Filed November 03, 2016

Section 16 reporting ended · disclosed 2016-11-03. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common Stock, par value $0.001SEC Table I · non-derivative	Direct	Reported balance After 2016-11-01 transaction · row 1 1 source row Row 1 · 2016-11-01 · Other · Disposed 11 · Balance 0 F1: Shares tendered for an offer price of $28.35 per share in cash (the "Closing Amount"), plus one non-transferable contingent value right per share (each, a "CVR"), which represents the contractual right to receive one or more payments in cash of up to $49.84 per share in the aggregate, contingent upon the achievement of certain milestones, in each case without any interest thereon and subject to any required tax withholdings , pursuant to the tender offer consummated on November 1, 2016 according to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated September 19, 2016, by and among the Issuer, Allegan Holdco US, Inc.("Parent") and Sapphire Acquisition Corp. ("Purchaser"), pursuant to which Purchaser was merged with and into Issuer (the "Merger").
Common Stock, par value $0.001SEC Table I · non-derivative	IndirectHeld by children of Reporting Person	Reported balance After 2016-11-01 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2016-11-01 · Other · Disposed 5 · Balance 0 F1: Shares tendered for an offer price of $28.35 per share in cash (the "Closing Amount"), plus one non-transferable contingent value right per share (each, a "CVR"), which represents the contractual right to receive one or more payments in cash of up to $49.84 per share in the aggregate, contingent upon the achievement of certain milestones, in each case without any interest thereon and subject to any required tax withholdings , pursuant to the tender offer consummated on November 1, 2016 according to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated September 19, 2016, by and among the Issuer, Allegan Holdco US, Inc.("Parent") and Sapphire Acquisition Corp. ("Purchaser"), pursuant to which Purchaser was merged with and into Issuer (the "Merger").
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $58.23 · Expires 2024-06-12	Direct	Reported balance After 2016-11-01 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2016-11-01 · Disposition to issuer · Disposed 5,666 · Balance 0 F2: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated September 19, 2016, by and among the Issuer, Allergan Holdco US, Inc. ("Parent") and Sapphire Acquisition Corp. ("Purchaser"), pursuant to which Purchaser was merged with and into Issuer (the "Merger"), each option to purchase shares (a "Company Option") of common stock, par value $0.001 per share, of Tobira Therapeutics, Inc. (the "Shares") that was then outstanding and unexercised, whether or not vested and which had a per-Share exercise price less than $28.35 per Share in cash (the "Closing Amount") (each, an "In the Money Option"), was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) the Closing Amount over (y) the exercise price payable per Share under such In the Money Option, multiplied by (B) the total number of Shares subject to such In the Money Option immediately prior to the effective time of the Merger (the "Effective Time") F3: (continued from Footnote 1) and (ii) a contingent value right with respect to the total number of Shares subject to such In the Money Option immediately prior to the Effective Time. At the Effective Time, each Company Option other than an In the Money Option that was then outstanding and unexercised, whether or not vested (each, an "Out of the Money Option"), was cancelled and converted into the right to receive a cash payment, if any, from Parent with respect to each Share subject to such Out of the Money Option upon each date that a payment would be required to a holder of a contingent value right under the terms of the Contingent Value Rights Agreement ("CVR Agreement") on or prior to the fifth anniversary of the Effective Time (each such date, a "Valuation Point"), F4: (continued from Footnote 1) equal to (i) the amount by which the sum of (A) the Closing Amount, (B) the amount per Share previously paid in respect of any earlier Valuation Points and (C) the amount per Share in cash to be paid at such Valuation Point under the CVR Agreement exceeds the exercise price payable per Share under such Out of the Money Option, less (ii) the amount of all payments previously received with respect to such Out of the Money Option. Notwithstanding the foregoing description, any Out of the Money Options with an exercise price payable per Share equal to or greater than $78.19 were cancelled at the Effective Time without any consideration payable therefor. F5: The Shares subject to this option were fully vested immediately prior to the Effective Time.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.52 · Expires 2025-07-08	Direct	Reported balance After 2016-11-01 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2016-11-01 · Disposition to issuer · Disposed 15,500 · Balance 0 F2: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated September 19, 2016, by and among the Issuer, Allergan Holdco US, Inc. ("Parent") and Sapphire Acquisition Corp. ("Purchaser"), pursuant to which Purchaser was merged with and into Issuer (the "Merger"), each option to purchase shares (a "Company Option") of common stock, par value $0.001 per share, of Tobira Therapeutics, Inc. (the "Shares") that was then outstanding and unexercised, whether or not vested and which had a per-Share exercise price less than $28.35 per Share in cash (the "Closing Amount") (each, an "In the Money Option"), was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) the Closing Amount over (y) the exercise price payable per Share under such In the Money Option, multiplied by (B) the total number of Shares subject to such In the Money Option immediately prior to the effective time of the Merger (the "Effective Time") F3: (continued from Footnote 1) and (ii) a contingent value right with respect to the total number of Shares subject to such In the Money Option immediately prior to the Effective Time. At the Effective Time, each Company Option other than an In the Money Option that was then outstanding and unexercised, whether or not vested (each, an "Out of the Money Option"), was cancelled and converted into the right to receive a cash payment, if any, from Parent with respect to each Share subject to such Out of the Money Option upon each date that a payment would be required to a holder of a contingent value right under the terms of the Contingent Value Rights Agreement ("CVR Agreement") on or prior to the fifth anniversary of the Effective Time (each such date, a "Valuation Point"), F4: (continued from Footnote 1) equal to (i) the amount by which the sum of (A) the Closing Amount, (B) the amount per Share previously paid in respect of any earlier Valuation Points and (C) the amount per Share in cash to be paid at such Valuation Point under the CVR Agreement exceeds the exercise price payable per Share under such Out of the Money Option, less (ii) the amount of all payments previously received with respect to such Out of the Money Option. Notwithstanding the foregoing description, any Out of the Money Options with an exercise price payable per Share equal to or greater than $78.19 were cancelled at the Effective Time without any consideration payable therefor. F5: The Shares subject to this option were fully vested immediately prior to the Effective Time.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.91 · Expires 2026-01-12	Direct	Reported balance After 2016-11-01 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2016-11-01 · Disposition to issuer · Disposed 17,778 · Balance 0 F2: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated September 19, 2016, by and among the Issuer, Allergan Holdco US, Inc. ("Parent") and Sapphire Acquisition Corp. ("Purchaser"), pursuant to which Purchaser was merged with and into Issuer (the "Merger"), each option to purchase shares (a "Company Option") of common stock, par value $0.001 per share, of Tobira Therapeutics, Inc. (the "Shares") that was then outstanding and unexercised, whether or not vested and which had a per-Share exercise price less than $28.35 per Share in cash (the "Closing Amount") (each, an "In the Money Option"), was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) the Closing Amount over (y) the exercise price payable per Share under such In the Money Option, multiplied by (B) the total number of Shares subject to such In the Money Option immediately prior to the effective time of the Merger (the "Effective Time") F3: (continued from Footnote 1) and (ii) a contingent value right with respect to the total number of Shares subject to such In the Money Option immediately prior to the Effective Time. At the Effective Time, each Company Option other than an In the Money Option that was then outstanding and unexercised, whether or not vested (each, an "Out of the Money Option"), was cancelled and converted into the right to receive a cash payment, if any, from Parent with respect to each Share subject to such Out of the Money Option upon each date that a payment would be required to a holder of a contingent value right under the terms of the Contingent Value Rights Agreement ("CVR Agreement") on or prior to the fifth anniversary of the Effective Time (each such date, a "Valuation Point"), F4: (continued from Footnote 1) equal to (i) the amount by which the sum of (A) the Closing Amount, (B) the amount per Share previously paid in respect of any earlier Valuation Points and (C) the amount per Share in cash to be paid at such Valuation Point under the CVR Agreement exceeds the exercise price payable per Share under such Out of the Money Option, less (ii) the amount of all payments previously received with respect to such Out of the Money Option. Notwithstanding the foregoing description, any Out of the Money Options with an exercise price payable per Share equal to or greater than $78.19 were cancelled at the Effective Time without any consideration payable therefor. F5: The Shares subject to this option were fully vested immediately prior to the Effective Time.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.19 · Expires 2025-01-01	Direct	Reported balance After 2016-11-01 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2016-11-01 · Disposition to issuer · Disposed 17,695 · Balance 0 F2: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated September 19, 2016, by and among the Issuer, Allergan Holdco US, Inc. ("Parent") and Sapphire Acquisition Corp. ("Purchaser"), pursuant to which Purchaser was merged with and into Issuer (the "Merger"), each option to purchase shares (a "Company Option") of common stock, par value $0.001 per share, of Tobira Therapeutics, Inc. (the "Shares") that was then outstanding and unexercised, whether or not vested and which had a per-Share exercise price less than $28.35 per Share in cash (the "Closing Amount") (each, an "In the Money Option"), was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) the Closing Amount over (y) the exercise price payable per Share under such In the Money Option, multiplied by (B) the total number of Shares subject to such In the Money Option immediately prior to the effective time of the Merger (the "Effective Time") F3: (continued from Footnote 1) and (ii) a contingent value right with respect to the total number of Shares subject to such In the Money Option immediately prior to the Effective Time. At the Effective Time, each Company Option other than an In the Money Option that was then outstanding and unexercised, whether or not vested (each, an "Out of the Money Option"), was cancelled and converted into the right to receive a cash payment, if any, from Parent with respect to each Share subject to such Out of the Money Option upon each date that a payment would be required to a holder of a contingent value right under the terms of the Contingent Value Rights Agreement ("CVR Agreement") on or prior to the fifth anniversary of the Effective Time (each such date, a "Valuation Point"), F4: (continued from Footnote 1) equal to (i) the amount by which the sum of (A) the Closing Amount, (B) the amount per Share previously paid in respect of any earlier Valuation Points and (C) the amount per Share in cash to be paid at such Valuation Point under the CVR Agreement exceeds the exercise price payable per Share under such Out of the Money Option, less (ii) the amount of all payments previously received with respect to such Out of the Money Option. Notwithstanding the foregoing description, any Out of the Money Options with an exercise price payable per Share equal to or greater than $78.19 were cancelled at the Effective Time without any consideration payable therefor. F5: The Shares subject to this option were fully vested immediately prior to the Effective Time.

Filing footnotes · ownership attribution and instrument terms

F1: Shares tendered for an offer price of $28.35 per share in cash (the "Closing Amount"), plus one non-transferable contingent value right per share (each, a "CVR"), which represents the contractual right to receive one or more payments in cash of up to $49.84 per share in the aggregate, contingent upon the achievement of certain milestones, in each case without any interest thereon and subject to any required tax withholdings , pursuant to the tender offer consummated on November 1, 2016 according to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated September 19, 2016, by and among the Issuer, Allegan Holdco US, Inc.("Parent") and Sapphire Acquisition Corp. ("Purchaser"), pursuant to which Purchaser was merged with and into Issuer (the "Merger").

F2: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated September 19, 2016, by and among the Issuer, Allergan Holdco US, Inc. ("Parent") and Sapphire Acquisition Corp. ("Purchaser"), pursuant to which Purchaser was merged with and into Issuer (the "Merger"), each option to purchase shares (a "Company Option") of common stock, par value $0.001 per share, of Tobira Therapeutics, Inc. (the "Shares") that was then outstanding and unexercised, whether or not vested and which had a per-Share exercise price less than $28.35 per Share in cash (the "Closing Amount") (each, an "In the Money Option"), was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) the Closing Amount over (y) the exercise price payable per Share under such In the Money Option, multiplied by (B) the total number of Shares subject to such In the Money Option immediately prior to the effective time of the Merger (the "Effective Time")

F3: (continued from Footnote 1) and (ii) a contingent value right with respect to the total number of Shares subject to such In the Money Option immediately prior to the Effective Time. At the Effective Time, each Company Option other than an In the Money Option that was then outstanding and unexercised, whether or not vested (each, an "Out of the Money Option"), was cancelled and converted into the right to receive a cash payment, if any, from Parent with respect to each Share subject to such Out of the Money Option upon each date that a payment would be required to a holder of a contingent value right under the terms of the Contingent Value Rights Agreement ("CVR Agreement") on or prior to the fifth anniversary of the Effective Time (each such date, a "Valuation Point"),

F4: (continued from Footnote 1) equal to (i) the amount by which the sum of (A) the Closing Amount, (B) the amount per Share previously paid in respect of any earlier Valuation Points and (C) the amount per Share in cash to be paid at such Valuation Point under the CVR Agreement exceeds the exercise price payable per Share under such Out of the Money Option, less (ii) the amount of all payments previously received with respect to such Out of the Money Option. Notwithstanding the foregoing description, any Out of the Money Options with an exercise price payable per Share equal to or greater than $78.19 were cancelled at the Effective Time without any consideration payable therefor.

F5: The Shares subject to this option were fully vested immediately prior to the Effective Time.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
May 28, 2026 Filed May 29, 2026 20:04 UTC	Immunovant, Inc. IMVT · Entity 3632	Exercise / conversionStock Option (right to buy) · Derivative	16,260	$0.00 Strike: $14.70	$0.00	Disclosure SEC source: 0001341896-26-000004 · wk-form4_1780085096.xml · derivative · entry 10 Fromkin Andrew J. · CIK 0001341896 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,260 shares Expires 2033-04-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Reflects an award of stock options to purchase Common Shares that is fully vested. Read SEC document
May 28, 2026 Filed May 29, 2026 20:04 UTC	Immunovant, Inc. IMVT · Entity 3632	Exercise / conversionStock Option (right to buy) · Derivative	77,181	$0.00 Strike: $8.43	$0.00	Disclosure SEC source: 0001341896-26-000004 · wk-form4_1780085096.xml · derivative · entry 9 Fromkin Andrew J. · CIK 0001341896 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 77,181 shares Expires 2029-11-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Reflects an award of stock options to purchase Common Shares that is fully vested. Read SEC document
May 28, 2026 Filed May 29, 2026 20:04 UTC	Immunovant, Inc. IMVT · Entity 3632	Exercise / conversionStock Option (right to buy) · Derivative	71,492	$0.00 Strike: $7.94	$0.00	Disclosure SEC source: 0001341896-26-000004 · wk-form4_1780085096.xml · derivative · entry 8 Fromkin Andrew J. · CIK 0001341896 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 71,492 shares Expires 2032-01-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Reflects an award of stock options to purchase Common Shares that is fully vested. Read SEC document
May 28, 2026 Filed May 29, 2026 20:04 UTC	Immunovant, Inc. IMVT · Entity 3632	Exercise / conversionStock Option (right to buy) · Derivative	31,668	$0.00 Strike: $4.99	$0.00	Disclosure SEC source: 0001341896-26-000004 · wk-form4_1780085096.xml · derivative · entry 7 Fromkin Andrew J. · CIK 0001341896 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 31,668 shares Expires 2032-08-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Reflects an award of stock options to purchase Common Shares that is fully vested. Read SEC document
May 28, 2026 Filed May 29, 2026 20:04 UTC	Immunovant, Inc. IMVT · Entity 3632	SaleCommon Stock	210,468	$33.56	$7,063,306.08	Disclosure SEC source: 0001341896-26-000004 · wk-form4_1780085096.xml · nonDerivative · entry 6 Fromkin Andrew J. · CIK 0001341896 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,382 F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.04 - $33.85 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document
May 28, 2026 Filed May 29, 2026 20:04 UTC	Immunovant, Inc. IMVT · Entity 3632	SaleCommon Stock	11,483	$32.64	$374,805.12	Disclosure SEC source: 0001341896-26-000004 · wk-form4_1780085096.xml · nonDerivative · entry 5 Fromkin Andrew J. · CIK 0001341896 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 284,850 F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.04 - $33.035 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document
May 28, 2026 Filed May 29, 2026 20:04 UTC	Immunovant, Inc. IMVT · Entity 3632	Exercise / conversionCommon Stock	16,260	$14.70	$239,022.00	Disclosure SEC source: 0001341896-26-000004 · wk-form4_1780085096.xml · nonDerivative · entry 4 Fromkin Andrew J. · CIK 0001341896 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 296,333 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
May 28, 2026 Filed May 29, 2026 20:04 UTC	Immunovant, Inc. IMVT · Entity 3632	Exercise / conversionCommon Stock	77,181	$8.43	$650,635.83	Disclosure SEC source: 0001341896-26-000004 · wk-form4_1780085096.xml · nonDerivative · entry 3 Fromkin Andrew J. · CIK 0001341896 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 280,073 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
May 28, 2026 Filed May 29, 2026 20:04 UTC	Immunovant, Inc. IMVT · Entity 3632	Exercise / conversionCommon Stock	71,492	$7.94	$567,646.48	Disclosure SEC source: 0001341896-26-000004 · wk-form4_1780085096.xml · nonDerivative · entry 2 Fromkin Andrew J. · CIK 0001341896 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 202,892 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
May 28, 2026 Filed May 29, 2026 20:04 UTC	Immunovant, Inc. IMVT · Entity 3632	Exercise / conversionCommon Stock	31,668	$4.99	$158,023.32	Disclosure SEC source: 0001341896-26-000004 · wk-form4_1780085096.xml · nonDerivative · entry 1 Fromkin Andrew J. · CIK 0001341896 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 131,400 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
April 07, 2026 Filed Apr 9, 2026 20:28 UTC	Immunovant, Inc. IMVT · Entity 3632	GrantStock Option (right to buy) · Derivative	7,061	$0.00 Strike: $24.61	$0.00	Disclosure SEC source: 0001764013-26-000050 · wk-form4_1775766526.xml · derivative · entry 2 Fromkin Andrew J. · CIK 0001341896 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,061 Underlying: Common Stock · 7,061 shares Expires 2036-04-07 F2 · derivative.exercise_date: These options were granted pursuant to the Plan. The shares underlying the options will vest on April 1, 2027, subject to the Reporting Person's continuous service to the Issuer as of such date. Read SEC document
April 07, 2026 Filed Apr 9, 2026 20:28 UTC	Immunovant, Inc. IMVT · Entity 3632	GrantCommon Stock	13,880	$0.00	$0.00	Disclosure SEC source: 0001764013-26-000050 · wk-form4_1775766526.xml · nonDerivative · entry 1 Fromkin Andrew J. · CIK 0001341896 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 99,732 F1 · shares: These restricted stock units ("RSUs") were granted pursuant to the Issuer's 2019 Equity Incentive Plan (the "Plan"). Each RSU represents a contingent right to receive one share of common stock upon the vesting of the unit. The RSUs will vest in full on April 1, 2027, subject to the Reporting Person's continuous service to the Issuer as of such date. The Reporting Person may elect to defer settlement of the RSUs upon vesting, subject to the requirements of Rule 409A. Read SEC document
December 01, 2025 Filed Dec 3, 2025 23:14 UTC	Immunovant, Inc. IMVT · Entity 3632	SaleCommon Stock	2,898	$23.95	$69,407.10	Disclosure SEC source: 0001764013-25-000160 · wk-form4_1764803692.xml · nonDerivative · entry 2 Fromkin Andrew J. · CIK 0001341896 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 85,852 F1 · shares: The sale of shares of common stock reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 6, 2024 in order to satisfy applicable tax obligations arising in connection with the vesting and deferred settlement of a prior award of restricted stock units. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.73 - $24.13 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document
December 01, 2025 Filed Dec 3, 2025 23:14 UTC	Immunovant, Inc. IMVT · Entity 3632	SaleCommon Stock	19,351	$23.14	$447,782.14	Disclosure SEC source: 0001764013-25-000160 · wk-form4_1764803692.xml · nonDerivative · entry 1 Fromkin Andrew J. · CIK 0001341896 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 88,750 F1 · shares: The sale of shares of common stock reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 6, 2024 in order to satisfy applicable tax obligations arising in connection with the vesting and deferred settlement of a prior award of restricted stock units. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.73 - $23.72 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document
April 01, 2025 Filed Apr 3, 2025 20:41 UTC	Immunovant, Inc. IMVT · Entity 3632	GrantStock Option (right to buy) · Derivative	7,600	$0.00 Strike: $15.20	$0.00	Disclosure SEC source: 0001764013-25-000043 · wk-form4_1743712868.xml · derivative · entry 2 Fromkin Andrew J. · CIK 0001341896 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,600 Underlying: Common Stock · 7,600 shares Expires 2035-04-01 F2 · derivative.exercise_date: The shares underlying the options will vest on April 1, 2026, subject to the Reporting Person's continuous service to the Issuer as of such date. Read SEC document
April 01, 2025 Filed Apr 3, 2025 20:41 UTC	Immunovant, Inc. IMVT · Entity 3632	GrantCommon Stock	16,188	$0.00	$0.00	Disclosure SEC source: 0001764013-25-000043 · wk-form4_1743712868.xml · nonDerivative · entry 1 Fromkin Andrew J. · CIK 0001341896 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 108,101 F1 · shares: These restricted stock units ("RSUs") were granted pursuant to the Issuer's 2019 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of common stock upon the vesting of the unit. The RSUs will vest in full on April 1, 2026, subject to the Reporting Person's continuous service to the Issuer as of such date. The Reporting Person may elect to defer settlement of the RSUs upon vesting, subject to the requirements of Rule 409A. Read SEC document
March 07, 2025 Filed Mar 11, 2025 20:18 UTC	Immunovant, Inc. IMVT · Entity 3632	SaleCommon Stock	1,384	$19.96	$27,624.64	Disclosure SEC source: 0001764013-25-000034 · wk-form4_1741724319.xml · nonDerivative · entry 2 Fromkin Andrew J. · CIK 0001341896 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 91,913 F1 · shares: The sale of shares of common stock reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 6, 2024 in order to satisfy applicable tax obligations arising in connection with the vesting and deferred settlement of a prior award of restricted stock units. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.91 - $20.00 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document
March 07, 2025 Filed Mar 11, 2025 20:18 UTC	Immunovant, Inc. IMVT · Entity 3632	SaleCommon Stock	6,616	$19.52	$129,144.32	Disclosure SEC source: 0001764013-25-000034 · wk-form4_1741724319.xml · nonDerivative · entry 1 Fromkin Andrew J. · CIK 0001341896 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 93,297 F1 · shares: The sale of shares of common stock reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 6, 2024 in order to satisfy applicable tax obligations arising in connection with the vesting and deferred settlement of a prior award of restricted stock units. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.91 - $19.86 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document
April 02, 2024 Filed Apr 4, 2024 20:54 UTC	Immunovant, Inc. IMVT · Entity 3632	GrantStock Option (right to buy) · Derivative	4,690	$0.00 Strike: $30.78	$0.00	Disclosure SEC source: 0001764013-24-000067 · wk-form4_1712264048.xml · derivative · entry 2 Fromkin Andrew J. · CIK 0001341896 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,690 Underlying: Common Stock · 4,690 shares Expires 2034-04-02 F2 · derivative.exercise_date: The shares underlying the options will vest on April 2, 2025, subject to the Reporting Person's continuous service to the Issuer as of such date. Read SEC document
April 02, 2024 Filed Apr 4, 2024 20:54 UTC	Immunovant, Inc. IMVT · Entity 3632	GrantCommon Stock	11,255	$0.00	$0.00	Disclosure SEC source: 0001764013-24-000067 · wk-form4_1712264048.xml · nonDerivative · entry 1 Fromkin Andrew J. · CIK 0001341896 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 99,913 F1 · shares: These restricted stock units ("RSUs") were granted pursuant to the Issuer's 2019 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of common stock upon the vesting of the unit. The RSUs will vest in full on April 2, 2025, subject to the Reporting Person's continuous service to the Issuer as of such date. The Reporting Person may elect to defer settlement of the RSUs upon vesting, subject to the requirements of Rule 409A. Read SEC document
December 01, 2023 Filed Dec 5, 2023 21:30 UTC	Immunovant, Inc. IMVT · Entity 3632	SaleCommon Stock	4,773	$40.46	$193,115.58	Disclosure SEC source: 0001764013-23-000156 · wk-form4_1701811810.xml · nonDerivative · entry 3 Fromkin Andrew J. · CIK 0001341896 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 88,658 F1 · security: Represents the sale of shares of common stock pursuant to a Rule 10b5-1 trading plan adopted on May 24, 2023, in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of the above award of restricted stock covering shares of common stock and does not represent a discretionary sale by the reporting person. F4 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $40.24 - $40.60 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4. Read SEC document
December 01, 2023 Filed Dec 5, 2023 21:30 UTC	Immunovant, Inc. IMVT · Entity 3632	SaleCommon Stock	3,636	$39.81	$144,749.16	Disclosure SEC source: 0001764013-23-000156 · wk-form4_1701811810.xml · nonDerivative · entry 2 Fromkin Andrew J. · CIK 0001341896 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 93,431 F1 · security: Represents the sale of shares of common stock pursuant to a Rule 10b5-1 trading plan adopted on May 24, 2023, in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of the above award of restricted stock covering shares of common stock and does not represent a discretionary sale by the reporting person. F3 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $39.22 - $40.19 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4. Read SEC document
December 01, 2023 Filed Dec 5, 2023 21:30 UTC	Immunovant, Inc. IMVT · Entity 3632	SaleCommon Stock	3,941	$38.78	$152,831.98	Disclosure SEC source: 0001764013-23-000156 · wk-form4_1701811810.xml · nonDerivative · entry 1 Fromkin Andrew J. · CIK 0001341896 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 97,067 F1 · security: Represents the sale of shares of common stock pursuant to a Rule 10b5-1 trading plan adopted on May 24, 2023, in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of the above award of restricted stock covering shares of common stock and does not represent a discretionary sale by the reporting person. F2 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $38.19 - $39.13 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4. Read SEC document
April 12, 2023 Filed Apr 14, 2023 20:33 UTC	Immunovant, Inc. IMVT · Entity 3632	GrantStock Option (right to buy) · Derivative	16,260	$0.00 Strike: $14.70	$0.00	Disclosure SEC source: 0001764013-23-000045 · wf-form4_168150437013871.xml · derivative · entry 2 Fromkin Andrew J. · CIK 0001341896 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,260 Underlying: Common Stock · 16,260 shares Expires 2033-04-12 F3 · derivative.exercise_date: The shares underlying the options vest one year after the date of grant on April 12, 2024, subject to the Reporting Person's continuous service to the Issuer as of such date. Read SEC document
April 12, 2023 Filed Apr 14, 2023 20:33 UTC	Immunovant, Inc. IMVT · Entity 3632	GrantCommon Stock	12,523	$0.00	$0.00	Disclosure SEC source: 0001764013-23-000045 · wf-form4_168150437013871.xml · nonDerivative · entry 1 Fromkin Andrew J. · CIK 0001341896 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 101,008 F1 · security: Represents the number of shares underlying restricted stock units awards ("RSUs"). F2 · shares: The RSUs vest in their entirety one year after the date of grant on April 12, 2024, subject to the Reporting Person's continued service to the Issuer as of such date; provided that the Reporting Person may elect to defer settlement of the RSUs upon vesting, subject to the requirements of Rule 409A. Read SEC document
August 17, 2022 Filed Aug 19, 2022 20:48 UTC	Immunovant, Inc. IMVT · Entity 3632	GrantStock Option (right to buy) · Derivative	31,668	$0.00 Strike: $4.99	$0.00	Disclosure SEC source: 0001764013-22-000097 · wf-form4_166094208760439.xml · derivative · entry 2 Fromkin Andrew J. · CIK 0001341896 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,668 Underlying: Common Stock · 31,668 shares Expires 2032-08-17 F3 · derivative.exercise_date: The shares underlying the options vest one year after the date of grant on August 17, 2023, subject to the Reporting Person's continuous service to the Issuer as of such date. Read SEC document
August 17, 2022 Filed Aug 19, 2022 20:48 UTC	Immunovant, Inc. IMVT · Entity 3632	GrantCommon Stock	21,059	$0.00	$0.00	Disclosure SEC source: 0001764013-22-000097 · wf-form4_166094208760439.xml · nonDerivative · entry 1 Fromkin Andrew J. · CIK 0001341896 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,485 F1 · security: Represents the number of shares underlying restricted stock units awards ("RSUs"). F2 · shares: The RSUs vest in their entirety one year after the date of grant on August 17, 2023, subject to the Reporting Person's continued service to the Issuer as of such date; provided that the Reporting Person may elect to defer settlement of the RSUs upon vesting, subject to the requirements of Rule 409A. Read SEC document
January 10, 2022 Filed Jan 12, 2022 22:09 UTC	Immunovant, Inc. IMVT · Entity 3632	GrantStock Option (right to buy) · Derivative	71,492	$0.00 Strike: $7.94	$0.00	Disclosure SEC source: 0001764013-22-000021 · wf-form4_164202534055827.xml · derivative · entry 2 Fromkin Andrew J. · CIK 0001341896 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 208,973 Underlying: Common Stock · 71,492 shares Expires 2032-01-10 F3 · derivative.exercise_date: Shares underlying the options vest over a period of two years, in a series of eight successive equal installments from the date of the award, subject to the Reporting Person providing continuous service to the Issuer as of each such date. Read SEC document
January 10, 2022 Filed Jan 12, 2022 22:09 UTC	Immunovant, Inc. IMVT · Entity 3632	GrantCommon Stock	21,726	$0.00	$0.00	Disclosure SEC source: 0001764013-22-000021 · wf-form4_164202534055827.xml · nonDerivative · entry 1 Fromkin Andrew J. · CIK 0001341896 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,426 F1 · security: Represents the number of shares underlying restricted stock units awards ("RSUs"). F2 · shares: The RSUs vest over a period of two years, in a series of eight successive equal installments from the date of the award, subject to the Reporting Person providing continuous service to the Issuer as of each such date. Read SEC document
August 10, 2021 Filed Aug 11, 2021 18:12 UTC	Immunovant, Inc. IMVT · Entity 3632	PurchaseCommon Stock	5,500	$7.90	$43,450.00	Disclosure SEC source: 0001764013-21-000081 · wf-form4_162870554557188.xml · nonDerivative · entry 1 Fromkin Andrew J. · CIK 0001341896 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,700 Read SEC document
March 19, 2021 Filed Mar 23, 2021 12:50 UTC	Immunovant, Inc. IMVT · Entity 3632	GrantStock Option (right to buy) · Derivative	23,300	$0.00 Strike: $17.00	$0.00	Disclosure SEC source: 0001764013-21-000041 · wf-form4_161650380299067.xml · derivative · entry 2 Fromkin Andrew J. · CIK 0001341896 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,300 Underlying: Common Stock · 23,300 shares Expires 2031-03-19 F2 · derivative.exercise_date: The shares underlying the options vest one year after the date of grant on March 19, 2022, subject to the Reporting Person's continuous service to the Issuer as of such date. Read SEC document
March 19, 2021 Filed Mar 23, 2021 12:50 UTC	Immunovant, Inc. IMVT · Entity 3632	GrantCommon Stock	15,500	$0.00	$0.00	Disclosure SEC source: 0001764013-21-000041 · wf-form4_161650380299067.xml · nonDerivative · entry 1 Fromkin Andrew J. · CIK 0001341896 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,200 F1 · shares: Represents the number of shares underlying restricted stock unit awards ("RSUs") granted to the Reporting Person pursuant to a non-employee director grant. Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest in their entirety one year after the date of grant on March 19, 2022, subject to the Reporting Person's continued service to the Issuer as of such date; provided that the Reporting Person may elect to defer settlement of the RSUs upon vesting, subject to the requirements of Rule 409A. Read SEC document
May 15, 2020 Filed May 18, 2020 12:40 UTC	Immunovant, Inc. IMVT · Entity 3632	GrantStock Option (right to buy) · Derivative	37,000	$0.00 Strike: $19.01	$0.00	Disclosure SEC source: 0001209191-20-029934 · doc4.xml · derivative · entry 2 Fromkin Andrew J. · CIK 0001341896 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,000 Underlying: Common Stock · 37,000 shares Expires 2030-05-14 F2 · derivative.exercise_date: The shares underlying the option vest in eight equal quarterly installments measured from May 15, 2020, subject to the Reporting Person providing continuous service to the Issuer as of each such date. Read SEC document
May 15, 2020 Filed May 18, 2020 12:40 UTC	Immunovant, Inc. IMVT · Entity 3632	GrantCommon Stock	24,700	$0.00	$0.00	Disclosure SEC source: 0001209191-20-029934 · doc4.xml · nonDerivative · entry 1 Fromkin Andrew J. · CIK 0001341896 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,700 F1 · shares: Represents the number of shares underlying restricted stock units awards ("RSUs") pursuant to a non-employee director grant. Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest in two equal annual installments on May 15, 2021 and May 15, 2022, subject to the Reporting Person's continued service to the Issuer as of each such date; provided that each director may elect to defer settlement of the RSUs upon vesting, subject to Rule 409A regulation. F1 · price: Represents the number of shares underlying restricted stock units awards ("RSUs") pursuant to a non-employee director grant. Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest in two equal annual installments on May 15, 2021 and May 15, 2022, subject to the Reporting Person's continued service to the Issuer as of each such date; provided that each director may elect to defer settlement of the RSUs upon vesting, subject to Rule 409A regulation. Read SEC document
December 18, 2019 Filed Dec 20, 2019 21:51 UTC	Immunovant, Inc. IMVT · Entity 3632	GrantStock Option (right to buy) · Derivative	77,181	Not disclosed Strike: $8.43	Not disclosed	Disclosure SEC source: 0001209191-19-061588 · doc4.xml · derivative · entry 1 Fromkin Andrew J. · CIK 0001341896 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,181 Underlying: Common Stock · 77,181 shares Expires 2029-11-19 F2 · price: In connection with the share exchange transaction pursuant to which Health Sciences Acquisitions Corporation ("HSAC") acquired 100% of the issued and outstanding shares of Immunovant Sciences Ltd., the option to purchase 157,812 shares of Immunovant Sciences Ltd. at exercise price of $4.12 per share, was assumed by HSAC and converted into an option to purchase shares of the Issuer (formerly known as HSAC). F1 · derivative.exercise_date: This stock option vests over a period of three years, with 1/3 of the shares underlying the option vesting on each of the first, second and third anniversaries of the vesting commencement date. Read SEC document
November 01, 2016 Filed Nov 3, 2016 14:28 UTC	Tobira Therapeutics, Inc. TBRA · Entity 181299	Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative	17,695	Not disclosed Strike: $8.19	Not disclosed	Disclosure SEC source: 0001209191-16-148105 · doc4.xml · derivative · entry 6 Fromkin Andrew J. · CIK 0001341896 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,695 shares Expires 2025-01-01 F2 · price: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated September 19, 2016, by and among the Issuer, Allergan Holdco US, Inc. ("Parent") and Sapphire Acquisition Corp. ("Purchaser"), pursuant to which Purchaser was merged with and into Issuer (the "Merger"), each option to purchase shares (a "Company Option") of common stock, par value $0.001 per share, of Tobira Therapeutics, Inc. (the "Shares") that was then outstanding and unexercised, whether or not vested and which had a per-Share exercise price less than $28.35 per Share in cash (the "Closing Amount") (each, an "In the Money Option"), was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) the Closing Amount over (y) the exercise price payable per Share under such In the Money Option, multiplied by (B) the total number of Shares subject to such In the Money Option immediately prior to the effective time of the Merger (the "Effective Time") F3 · price: (continued from Footnote 1) and (ii) a contingent value right with respect to the total number of Shares subject to such In the Money Option immediately prior to the Effective Time. At the Effective Time, each Company Option other than an In the Money Option that was then outstanding and unexercised, whether or not vested (each, an "Out of the Money Option"), was cancelled and converted into the right to receive a cash payment, if any, from Parent with respect to each Share subject to such Out of the Money Option upon each date that a payment would be required to a holder of a contingent value right under the terms of the Contingent Value Rights Agreement ("CVR Agreement") on or prior to the fifth anniversary of the Effective Time (each such date, a "Valuation Point"), F4 · price: (continued from Footnote 1) equal to (i) the amount by which the sum of (A) the Closing Amount, (B) the amount per Share previously paid in respect of any earlier Valuation Points and (C) the amount per Share in cash to be paid at such Valuation Point under the CVR Agreement exceeds the exercise price payable per Share under such Out of the Money Option, less (ii) the amount of all payments previously received with respect to such Out of the Money Option. Notwithstanding the foregoing description, any Out of the Money Options with an exercise price payable per Share equal to or greater than $78.19 were cancelled at the Effective Time without any consideration payable therefor. F2 · derivative.exercise_date: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated September 19, 2016, by and among the Issuer, Allergan Holdco US, Inc. ("Parent") and Sapphire Acquisition Corp. ("Purchaser"), pursuant to which Purchaser was merged with and into Issuer (the "Merger"), each option to purchase shares (a "Company Option") of common stock, par value $0.001 per share, of Tobira Therapeutics, Inc. (the "Shares") that was then outstanding and unexercised, whether or not vested and which had a per-Share exercise price less than $28.35 per Share in cash (the "Closing Amount") (each, an "In the Money Option"), was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) the Closing Amount over (y) the exercise price payable per Share under such In the Money Option, multiplied by (B) the total number of Shares subject to such In the Money Option immediately prior to the effective time of the Merger (the "Effective Time") F3 · derivative.exercise_date: (continued from Footnote 1) and (ii) a contingent value right with respect to the total number of Shares subject to such In the Money Option immediately prior to the Effective Time. At the Effective Time, each Company Option other than an In the Money Option that was then outstanding and unexercised, whether or not vested (each, an "Out of the Money Option"), was cancelled and converted into the right to receive a cash payment, if any, from Parent with respect to each Share subject to such Out of the Money Option upon each date that a payment would be required to a holder of a contingent value right under the terms of the Contingent Value Rights Agreement ("CVR Agreement") on or prior to the fifth anniversary of the Effective Time (each such date, a "Valuation Point"), F4 · derivative.exercise_date: (continued from Footnote 1) equal to (i) the amount by which the sum of (A) the Closing Amount, (B) the amount per Share previously paid in respect of any earlier Valuation Points and (C) the amount per Share in cash to be paid at such Valuation Point under the CVR Agreement exceeds the exercise price payable per Share under such Out of the Money Option, less (ii) the amount of all payments previously received with respect to such Out of the Money Option. Notwithstanding the foregoing description, any Out of the Money Options with an exercise price payable per Share equal to or greater than $78.19 were cancelled at the Effective Time without any consideration payable therefor. F5 · derivative.exercise_date: The Shares subject to this option were fully vested immediately prior to the Effective Time. Read SEC document
November 01, 2016 Filed Nov 3, 2016 14:28 UTC	Tobira Therapeutics, Inc. TBRA · Entity 181299	Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative	17,778	Not disclosed Strike: $7.91	Not disclosed	Disclosure SEC source: 0001209191-16-148105 · doc4.xml · derivative · entry 5 Fromkin Andrew J. · CIK 0001341896 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,778 shares Expires 2026-01-12 F2 · price: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated September 19, 2016, by and among the Issuer, Allergan Holdco US, Inc. ("Parent") and Sapphire Acquisition Corp. ("Purchaser"), pursuant to which Purchaser was merged with and into Issuer (the "Merger"), each option to purchase shares (a "Company Option") of common stock, par value $0.001 per share, of Tobira Therapeutics, Inc. (the "Shares") that was then outstanding and unexercised, whether or not vested and which had a per-Share exercise price less than $28.35 per Share in cash (the "Closing Amount") (each, an "In the Money Option"), was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) the Closing Amount over (y) the exercise price payable per Share under such In the Money Option, multiplied by (B) the total number of Shares subject to such In the Money Option immediately prior to the effective time of the Merger (the "Effective Time") F3 · price: (continued from Footnote 1) and (ii) a contingent value right with respect to the total number of Shares subject to such In the Money Option immediately prior to the Effective Time. At the Effective Time, each Company Option other than an In the Money Option that was then outstanding and unexercised, whether or not vested (each, an "Out of the Money Option"), was cancelled and converted into the right to receive a cash payment, if any, from Parent with respect to each Share subject to such Out of the Money Option upon each date that a payment would be required to a holder of a contingent value right under the terms of the Contingent Value Rights Agreement ("CVR Agreement") on or prior to the fifth anniversary of the Effective Time (each such date, a "Valuation Point"), F4 · price: (continued from Footnote 1) equal to (i) the amount by which the sum of (A) the Closing Amount, (B) the amount per Share previously paid in respect of any earlier Valuation Points and (C) the amount per Share in cash to be paid at such Valuation Point under the CVR Agreement exceeds the exercise price payable per Share under such Out of the Money Option, less (ii) the amount of all payments previously received with respect to such Out of the Money Option. Notwithstanding the foregoing description, any Out of the Money Options with an exercise price payable per Share equal to or greater than $78.19 were cancelled at the Effective Time without any consideration payable therefor. F2 · derivative.exercise_date: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated September 19, 2016, by and among the Issuer, Allergan Holdco US, Inc. ("Parent") and Sapphire Acquisition Corp. ("Purchaser"), pursuant to which Purchaser was merged with and into Issuer (the "Merger"), each option to purchase shares (a "Company Option") of common stock, par value $0.001 per share, of Tobira Therapeutics, Inc. (the "Shares") that was then outstanding and unexercised, whether or not vested and which had a per-Share exercise price less than $28.35 per Share in cash (the "Closing Amount") (each, an "In the Money Option"), was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) the Closing Amount over (y) the exercise price payable per Share under such In the Money Option, multiplied by (B) the total number of Shares subject to such In the Money Option immediately prior to the effective time of the Merger (the "Effective Time") F3 · derivative.exercise_date: (continued from Footnote 1) and (ii) a contingent value right with respect to the total number of Shares subject to such In the Money Option immediately prior to the Effective Time. At the Effective Time, each Company Option other than an In the Money Option that was then outstanding and unexercised, whether or not vested (each, an "Out of the Money Option"), was cancelled and converted into the right to receive a cash payment, if any, from Parent with respect to each Share subject to such Out of the Money Option upon each date that a payment would be required to a holder of a contingent value right under the terms of the Contingent Value Rights Agreement ("CVR Agreement") on or prior to the fifth anniversary of the Effective Time (each such date, a "Valuation Point"), F4 · derivative.exercise_date: (continued from Footnote 1) equal to (i) the amount by which the sum of (A) the Closing Amount, (B) the amount per Share previously paid in respect of any earlier Valuation Points and (C) the amount per Share in cash to be paid at such Valuation Point under the CVR Agreement exceeds the exercise price payable per Share under such Out of the Money Option, less (ii) the amount of all payments previously received with respect to such Out of the Money Option. Notwithstanding the foregoing description, any Out of the Money Options with an exercise price payable per Share equal to or greater than $78.19 were cancelled at the Effective Time without any consideration payable therefor. F5 · derivative.exercise_date: The Shares subject to this option were fully vested immediately prior to the Effective Time. Read SEC document
November 01, 2016 Filed Nov 3, 2016 14:28 UTC	Tobira Therapeutics, Inc. TBRA · Entity 181299	Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative	15,500	Not disclosed Strike: $16.52	Not disclosed	Disclosure SEC source: 0001209191-16-148105 · doc4.xml · derivative · entry 4 Fromkin Andrew J. · CIK 0001341896 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,500 shares Expires 2025-07-08 F2 · price: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated September 19, 2016, by and among the Issuer, Allergan Holdco US, Inc. ("Parent") and Sapphire Acquisition Corp. ("Purchaser"), pursuant to which Purchaser was merged with and into Issuer (the "Merger"), each option to purchase shares (a "Company Option") of common stock, par value $0.001 per share, of Tobira Therapeutics, Inc. (the "Shares") that was then outstanding and unexercised, whether or not vested and which had a per-Share exercise price less than $28.35 per Share in cash (the "Closing Amount") (each, an "In the Money Option"), was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) the Closing Amount over (y) the exercise price payable per Share under such In the Money Option, multiplied by (B) the total number of Shares subject to such In the Money Option immediately prior to the effective time of the Merger (the "Effective Time") F3 · price: (continued from Footnote 1) and (ii) a contingent value right with respect to the total number of Shares subject to such In the Money Option immediately prior to the Effective Time. At the Effective Time, each Company Option other than an In the Money Option that was then outstanding and unexercised, whether or not vested (each, an "Out of the Money Option"), was cancelled and converted into the right to receive a cash payment, if any, from Parent with respect to each Share subject to such Out of the Money Option upon each date that a payment would be required to a holder of a contingent value right under the terms of the Contingent Value Rights Agreement ("CVR Agreement") on or prior to the fifth anniversary of the Effective Time (each such date, a "Valuation Point"), F4 · price: (continued from Footnote 1) equal to (i) the amount by which the sum of (A) the Closing Amount, (B) the amount per Share previously paid in respect of any earlier Valuation Points and (C) the amount per Share in cash to be paid at such Valuation Point under the CVR Agreement exceeds the exercise price payable per Share under such Out of the Money Option, less (ii) the amount of all payments previously received with respect to such Out of the Money Option. Notwithstanding the foregoing description, any Out of the Money Options with an exercise price payable per Share equal to or greater than $78.19 were cancelled at the Effective Time without any consideration payable therefor. F2 · derivative.exercise_date: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated September 19, 2016, by and among the Issuer, Allergan Holdco US, Inc. ("Parent") and Sapphire Acquisition Corp. ("Purchaser"), pursuant to which Purchaser was merged with and into Issuer (the "Merger"), each option to purchase shares (a "Company Option") of common stock, par value $0.001 per share, of Tobira Therapeutics, Inc. (the "Shares") that was then outstanding and unexercised, whether or not vested and which had a per-Share exercise price less than $28.35 per Share in cash (the "Closing Amount") (each, an "In the Money Option"), was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) the Closing Amount over (y) the exercise price payable per Share under such In the Money Option, multiplied by (B) the total number of Shares subject to such In the Money Option immediately prior to the effective time of the Merger (the "Effective Time") F3 · derivative.exercise_date: (continued from Footnote 1) and (ii) a contingent value right with respect to the total number of Shares subject to such In the Money Option immediately prior to the Effective Time. At the Effective Time, each Company Option other than an In the Money Option that was then outstanding and unexercised, whether or not vested (each, an "Out of the Money Option"), was cancelled and converted into the right to receive a cash payment, if any, from Parent with respect to each Share subject to such Out of the Money Option upon each date that a payment would be required to a holder of a contingent value right under the terms of the Contingent Value Rights Agreement ("CVR Agreement") on or prior to the fifth anniversary of the Effective Time (each such date, a "Valuation Point"), F4 · derivative.exercise_date: (continued from Footnote 1) equal to (i) the amount by which the sum of (A) the Closing Amount, (B) the amount per Share previously paid in respect of any earlier Valuation Points and (C) the amount per Share in cash to be paid at such Valuation Point under the CVR Agreement exceeds the exercise price payable per Share under such Out of the Money Option, less (ii) the amount of all payments previously received with respect to such Out of the Money Option. Notwithstanding the foregoing description, any Out of the Money Options with an exercise price payable per Share equal to or greater than $78.19 were cancelled at the Effective Time without any consideration payable therefor. F5 · derivative.exercise_date: The Shares subject to this option were fully vested immediately prior to the Effective Time. Read SEC document
November 01, 2016 Filed Nov 3, 2016 14:28 UTC	Tobira Therapeutics, Inc. TBRA · Entity 181299	Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative	5,666	Not disclosed Strike: $58.23	Not disclosed	Disclosure SEC source: 0001209191-16-148105 · doc4.xml · derivative · entry 3 Fromkin Andrew J. · CIK 0001341896 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,666 shares Expires 2024-06-12 F2 · price: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated September 19, 2016, by and among the Issuer, Allergan Holdco US, Inc. ("Parent") and Sapphire Acquisition Corp. ("Purchaser"), pursuant to which Purchaser was merged with and into Issuer (the "Merger"), each option to purchase shares (a "Company Option") of common stock, par value $0.001 per share, of Tobira Therapeutics, Inc. (the "Shares") that was then outstanding and unexercised, whether or not vested and which had a per-Share exercise price less than $28.35 per Share in cash (the "Closing Amount") (each, an "In the Money Option"), was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) the Closing Amount over (y) the exercise price payable per Share under such In the Money Option, multiplied by (B) the total number of Shares subject to such In the Money Option immediately prior to the effective time of the Merger (the "Effective Time") F3 · price: (continued from Footnote 1) and (ii) a contingent value right with respect to the total number of Shares subject to such In the Money Option immediately prior to the Effective Time. At the Effective Time, each Company Option other than an In the Money Option that was then outstanding and unexercised, whether or not vested (each, an "Out of the Money Option"), was cancelled and converted into the right to receive a cash payment, if any, from Parent with respect to each Share subject to such Out of the Money Option upon each date that a payment would be required to a holder of a contingent value right under the terms of the Contingent Value Rights Agreement ("CVR Agreement") on or prior to the fifth anniversary of the Effective Time (each such date, a "Valuation Point"), F4 · price: (continued from Footnote 1) equal to (i) the amount by which the sum of (A) the Closing Amount, (B) the amount per Share previously paid in respect of any earlier Valuation Points and (C) the amount per Share in cash to be paid at such Valuation Point under the CVR Agreement exceeds the exercise price payable per Share under such Out of the Money Option, less (ii) the amount of all payments previously received with respect to such Out of the Money Option. Notwithstanding the foregoing description, any Out of the Money Options with an exercise price payable per Share equal to or greater than $78.19 were cancelled at the Effective Time without any consideration payable therefor. F2 · derivative.exercise_date: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated September 19, 2016, by and among the Issuer, Allergan Holdco US, Inc. ("Parent") and Sapphire Acquisition Corp. ("Purchaser"), pursuant to which Purchaser was merged with and into Issuer (the "Merger"), each option to purchase shares (a "Company Option") of common stock, par value $0.001 per share, of Tobira Therapeutics, Inc. (the "Shares") that was then outstanding and unexercised, whether or not vested and which had a per-Share exercise price less than $28.35 per Share in cash (the "Closing Amount") (each, an "In the Money Option"), was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) the Closing Amount over (y) the exercise price payable per Share under such In the Money Option, multiplied by (B) the total number of Shares subject to such In the Money Option immediately prior to the effective time of the Merger (the "Effective Time") F3 · derivative.exercise_date: (continued from Footnote 1) and (ii) a contingent value right with respect to the total number of Shares subject to such In the Money Option immediately prior to the Effective Time. At the Effective Time, each Company Option other than an In the Money Option that was then outstanding and unexercised, whether or not vested (each, an "Out of the Money Option"), was cancelled and converted into the right to receive a cash payment, if any, from Parent with respect to each Share subject to such Out of the Money Option upon each date that a payment would be required to a holder of a contingent value right under the terms of the Contingent Value Rights Agreement ("CVR Agreement") on or prior to the fifth anniversary of the Effective Time (each such date, a "Valuation Point"), F4 · derivative.exercise_date: (continued from Footnote 1) equal to (i) the amount by which the sum of (A) the Closing Amount, (B) the amount per Share previously paid in respect of any earlier Valuation Points and (C) the amount per Share in cash to be paid at such Valuation Point under the CVR Agreement exceeds the exercise price payable per Share under such Out of the Money Option, less (ii) the amount of all payments previously received with respect to such Out of the Money Option. Notwithstanding the foregoing description, any Out of the Money Options with an exercise price payable per Share equal to or greater than $78.19 were cancelled at the Effective Time without any consideration payable therefor. F5 · derivative.exercise_date: The Shares subject to this option were fully vested immediately prior to the Effective Time. Read SEC document
November 01, 2016 Filed Nov 3, 2016 14:28 UTC	Tobira Therapeutics, Inc. TBRA · Entity 181299	OtherCommon Stock, par value $0.001	5	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-16-148105 · doc4.xml · nonDerivative · entry 2 Fromkin Andrew J. · CIK 0001341896 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Held by children of Reporting Person Disclosed balance after: 0 F1 · price: Shares tendered for an offer price of $28.35 per share in cash (the "Closing Amount"), plus one non-transferable contingent value right per share (each, a "CVR"), which represents the contractual right to receive one or more payments in cash of up to $49.84 per share in the aggregate, contingent upon the achievement of certain milestones, in each case without any interest thereon and subject to any required tax withholdings , pursuant to the tender offer consummated on November 1, 2016 according to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated September 19, 2016, by and among the Issuer, Allegan Holdco US, Inc.("Parent") and Sapphire Acquisition Corp. ("Purchaser"), pursuant to which Purchaser was merged with and into Issuer (the "Merger"). Read SEC document
November 01, 2016 Filed Nov 3, 2016 14:28 UTC	Tobira Therapeutics, Inc. TBRA · Entity 181299	OtherCommon Stock, par value $0.001	11	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-16-148105 · doc4.xml · nonDerivative · entry 1 Fromkin Andrew J. · CIK 0001341896 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Shares tendered for an offer price of $28.35 per share in cash (the "Closing Amount"), plus one non-transferable contingent value right per share (each, a "CVR"), which represents the contractual right to receive one or more payments in cash of up to $49.84 per share in the aggregate, contingent upon the achievement of certain milestones, in each case without any interest thereon and subject to any required tax withholdings , pursuant to the tender offer consummated on November 1, 2016 according to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated September 19, 2016, by and among the Issuer, Allegan Holdco US, Inc.("Parent") and Sapphire Acquisition Corp. ("Purchaser"), pursuant to which Purchaser was merged with and into Issuer (the "Merger"). Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.